PAZOPANIB HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Pazopanib Hydrochloride patents expire, and what generic alternatives are available?
Pazopanib Hydrochloride is a drug marketed by Apotex, Sun Pharm, and Teva Pharms Inc. and is included in three NDAs.
The generic ingredient in PAZOPANIB HYDROCHLORIDE is pazopanib hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pazopanib Hydrochloride
A generic version of PAZOPANIB HYDROCHLORIDE was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
Summary for PAZOPANIB HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 102 |
Clinical Trials: | 284 |
Patent Applications: | 704 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PAZOPANIB HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PAZOPANIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alliance for Clinical Trials in Oncology | Phase 2/Phase 3 |
Shenzhen Chipscreen Biosciences Co.Ltd | Phase 2 |
Institut National du Cancer INCa-ARC_14820 | Phase 1/Phase 2 |
Pharmacology for PAZOPANIB HYDROCHLORIDE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for PAZOPANIB HYDROCHLORIDE
US Patents and Regulatory Information for PAZOPANIB HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217713-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sun Pharm | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 215837-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms Inc | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217517-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |